BUSINESS
Dr. Reddy’s preps semaglutide pill launch in FY27, as GLP‑1 market opens up in India
“We are ready with all formats, including the oral,” says M.V. Ramana, CEO of Branded Markets (India & Emerging Markets). Semaglutide is already approved by India’s Subject Expert Committee (SEC), and Dr. Reddy’s is now awaiting the final nod from the national drug regulator, the CDSCO.
BUSINESS
Biocon Q3 net profit zooms 475% to Rs 144 crore as generics, biosimilars lift operating performance
Biocon Ltd.’s December quarter net profit rose 475 percent to Rs.144 crore in Q3FY26 from Rs.25 crore a year earlier, primarily by lower exceptional losses, compared with the prior year, alongside higher other income, and improved profitability across its biosimilars and generics divisions.
BUSINESS
Lupin Q3 net profit climbs 37.4% in Q3FY26 on strong US, emerging‑market demand
The company’s net profit expanded sharply from Rs.858.9 crore a year earlier, buoyed by 54 percent growth (YoY) in US revenue to Rs 3113.2 crore, its highest ever.
BUSINESS
Dr Lal PathLabs readies a war chest for southern push as CFO Goel flags potential big‑ticket M&A, new bets in radiology and genomics
The balance sheet gives him room to move - Lal PathLabs is sitting on about Rs.1,400 crore of net cash and no debt, and can blend cash with equity, if a compelling platform emerges, Goel said.
BUSINESS
USV buys majority stake in Wellbeing Nutrition for Rs 1,250 crore
In the last two years, Wellbeing Nutrition has clocked 120% growth and is expected to cross Rs 450 crore in revenue by FY27
BUSINESS
OneSource gets Saudi nod for Ozempic generic, partner Hikma will commercialise
The approval by the Saudi Food and Drug Authority paves the way for commercialization through its exclusive regional partner Hikma Pharmaceuticals Plc, the largest drugmaker in the Middle East and North Africa by sales.
BUSINESS
Apollo HealthCo races toward Rs 25,000‑crore revenue target as digital losses narrow sharply
“They (Apollo HealthCo) are already going to be close to the Rs.20,000‑crore combined number this year… and by the end of next year, they should be getting closer to the Rs.25,000‑crore number with a 7 percent EBITDA margin,” Krishnan Akhileswaran, Group CFO told Moneycontrol.
BUSINESS
Divi’s Labs Q3 net profit slips 1% on labour‑code charge; revenue up 12%
Net profit for the December quarter fell 1 percent year‑on‑year to Rs.583 crore, compared with Rs.589 crore a year earlier, weighed down by a Rs.74‑crore exceptional charge arising from India’s newly notified labour codes.
BUSINESS
Apollo Hospitals’ Q3 net profit jumps 35%, Board declares Rs 10 interim dividend
The company attributed the profit surge to higher patient volumes, improved payer mix, and stronger profitability across HealthCo and healthcare services.
BUSINESS
Servier taps India as global hub for single‑pill combination drugs, targets 500 mn euro exports by 2030
The French drugmaker will invest 15 million euro in 2026 to build the platform, which will coordinate R&D, manufacturing partnerships and quality oversight in India.
BUSINESS
Zydus Lifesciences net profit rises 2% as labour-code provision, taxes weigh on earnings
Revenue from operations surged 30 percent YoY to Rs.6864.5 crore, driven by strong US generics performance, double‑digit growth in India formulations, a sharp jump in consumer wellness revenue due to the consolidation of Comfort Click, and a scale‑up in international markets.
BUSINESS
New trade framework cuts tariffs, to ease market delays for US medical devices
The statement says India will decide within six months of the deal’s start whether to accept US or international testing standards for exports, potentially cutting months of delay for US medical devices to enter market.
BUSINESS
Indian pharma secure temporary shield in US; final tariff call due within months
"Contingent on the findings of the U.S. Section 232 investigation of pharmaceuticals and pharmaceutical ingredients, India will receive negotiated outcomes with respect to generic pharmaceuticals and ingredients," the US-India joint statement said.
BUSINESS
Alembic Pharma pivots to US branded market, set to launch women's 'health antibiotic'
The company’s decision to enter the branded US segment is driven by sustained price pressure in generics, managing director Pranav Amin tells Moneycontrol
BUSINESS
A new report calls to develop, adopt non-animal lab testing tech to pivot India as R&D hub
For decades, animals have served as the default for drug testing, but the biological divide between species is proving costly. Currently, only about 10 percent of drugs that enter human trials receive approval.
BUSINESS
US-Based PE Fund 108 BioCapital invests $20 million Pinwheel Therapeutics
The fund counts among its backers the family office of Silver Lake’s Mike Bingle, Manipal Group’s Ranjan Pai, Bharat Serums’ Daftary family, Erba‑TransAsia’s Suresh Vazirani, and Paragon Partners’ Siddharth Parekh, along with several major US and global institutions.
BUSINESS
Max Healthcare Q3FY26 net profit rises 9% to Rs 344 crore
Operating margin slipped to 26.1 percent, down from 27.3 percent a year earlier, the company attributed the margin compression to several factors including discontinuation of high‑value patented chemotherapy drugs for institutional patients after restrictive pricing guidelines from CGHS, pre‑commissioning expenses as new brownfield capacity came online in Mohali, Nanavati Max and Max Smart and GST rate change.
BUSINESS
On World Cancer Day, Tata Trusts CEO flags late diagnosis crisis as India’s cancer cases set to surge 24% by 2030
The Tata Trusts, among India’s oldest philanthropic institutions, have become key players in national cancer care. Their network the largest spans 20 cancer hospitals across states including Assam, Andhra Pradesh, Jharkhand and Maharashtra, with more centres under construction.
BUSINESS
Report finds India targeting the wrong tobacco, 90% of use unregulated, beedis untaxed
Policies target cigarettes even though 90 percent of Indians consume beedis and smokeless tobacco.
BUSINESS
Emcure Pharma net profit jumps 48% in Q3FY26 on strong international business growth
Profit after tax rose to Rs 231 crore in Q3FY26 from Rs 156 crore a year earlier, despite an exceptional expense of Rs 38 crore linked to labour code changes.
BUSINESS
Mankind Pharma Q3 net profit rises 9.5% as BSV boost offsets acute weakness
Revenue from operations increased 11.5% to Rs.3,567 crore.
BUSINESS
Sun Pharma signals willingness to raise debt for acquisitions as cash pile swells to $3.2 bn
'US continues to be an important part of our focus, specifically for the innovative medicines… For emerging markets, we’re looking at tuck‑ins or smaller acquisitions,' Dilip Shanghvi said on M&A strategy. He added that Sun would pursue a deal 'only if we think that it can help us strengthen our long-term strategic capability'
BUSINESS
SPARC wins USFDA priority review voucher tied to Sezaby approval
PRVs are tradable vouchers issued by the USFDA to incentivize development of treatments for rare pediatric conditions, and can be redeemed to secure a priority review for a separate, future drug application—often shaving months off the review clock for high-value assets.
BUSINESS
India-US deal brings relief to nutraceutical exports after customers cut orders and inventories
India's nutraceutical exports, which accounts for almost $1 billion worth of exports, are reeling under severe stress, as US customers are cutting inventories, buying less, delaying launches and even asking for air freight, pushing costs higher.
